IRLAB publishes interim report for the period January – September 2026

Gothenburg, Sweden, November 13, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the interim report for the period January-September 2026, has been published.

IRLAB strengthens focus on revenue generation, initiates workforce reductions, and announces reduced likelihood of new partnership agreements in 2026

IRLAB: Invitation to the interim report for Q3 2026 presentation and webcast